Editorial: Incretin agonists in the treatment of obesity.

Sun, Xiaodong; Hu, Miaofen G; Li, Lixin

Sun, Xiaodong; Hu, Miaofen G; Li, Lixin.

Affiliation

Sun X; Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
Hu MG; Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, China.
Li L; Department of Medicine, Division of Hematology and Oncology, Tufts Medical Center, Boston, MA, United States.

Front Endocrinol (Lausanne) ; 14: 1265826, 2023.

Article in En | MEDLINE | ID: mdl-37621651

Subject(s)

Incretins; Obesity; Humans; Incretins/therapeutic use; Obesity/drug therapy

Key words

Dual GIP/GLP-1R agonists; GIP; GLP-1; GLP-1R agonists; incretins; liraglutide; obesity; semaglutide

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Incretins / Obesity Limits: Humans Language: En Journal: Front Endocrinol (Lausanne) Year: 2023 Document type: Article Affiliation country: China Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google